What if the bacteria in your gut could help fight cancer? Enterome is partnering with Bristol-Myers Squibb to explore this possibility and develop microbiome-related therapeutics and diagnostics for immuno-oncology.
Enterome, one of the coolest biotechs in Paris, specializes in the isolation of bacteria and microbial targets linked to immune modulation and inflammation. With an impressive record of partnerships, the company is now closing a deal with the big pharma Bristol-Myers Squibb to discover microbiome-related biomarkers, drug targets and therapeutic molecules for cancer therapies and diagnostics.
BMS will pay Enterome €14M ($15M) upfront, R&D funding, milestone payments and royalties for each candidate, although no details have been released. With this partnership, BMS expects to strengthen its immuno-oncology pipeline and improve patient outcomes by harnessing the close relationship between the microbiome and immune regulation.
As we discussed with Pierre Belichard, Enterome’s CEO, medical microbiomics is a rapidly growing field that may hold the key to personalized therapy. In the last decade, research has identified strong links between gut bacteria and human health.